Head-To-Head Review: HilleVax (NASDAQ:HLVX) and Entera Bio (NASDAQ:ENTX)

HilleVax (NASDAQ:HLVX) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.

Earnings & Valuation

This table compares HilleVax and Entera Bio’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HilleVax	N/A	N/A	-$123.57 million	($3.30)	-3.96
Entera Bio	$130,000.00	555.97	-$8.89 million	($0.28)	-7.21

Entera Bio has higher revenue and earnings than HilleVax. Entera Bio is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares HilleVax and Entera Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
HilleVax	N/A	-56.18%	-43.75%
Entera Bio	N/A	-103.40%	-85.00%

Analyst Recommendations

This is a summary of recent ratings and target prices for HilleVax and Entera Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HilleVax	0	0	4	0	3.00
Entera Bio	0	0	1	0	3.00

HilleVax presently has a consensus target price of $29.00, suggesting a potential upside of 121.88%. Entera Bio has a consensus target price of $10.00, suggesting a potential upside of 395.05%. Given Entera Bio’s higher possible upside, analysts plainly believe Entera Bio is more favorable than HilleVax.

Insider and Institutional Ownership

86.4% of HilleVax shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 71.1% of HilleVax shares are owned by company insiders. Comparatively, 8.9% of Entera Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

HilleVax has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500.

Summary

HilleVax beats Entera Bio on 6 of the 11 factors compared between the two stocks.

About HilleVax

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.